Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised ‘GISCAD’ trial
Roberto Labianca(Ospedale Papa Giovanni XXIII), Alberto Zaniboni(Fondazione Poliambulanza Istituto Ospedaliero), Dario Nicolella(Azienda Ospedaliera S.Giuseppe Moscati), Sara Lonardi(Istituto Oncologico Veneto), Giordano Beretta(Humanitas Gavazzeni), Domenico Corsi(Ospedale San Carlo), Massimo Aglietta(Verizon (United States)), Sandro Barni, Giuseppe Fornarini(Ospedale Policlinico San Martino), E. Dapretto(Azienda Ospedaliera San Gerardo), Enrico Cortesi(Sapienza University of Rome), Alberto F. Sobrero(Ospedale Policlinico San Martino), Irene Floriani(Mario Negri Institute for Pharmacological Research), L. Isa, D. Turci(Azienda Ospedaliera San Camillo-Forlanini)
Cited by 110
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k